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Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disorder, still of
unknown cause, that can affect the respiratory system with variable manifestations, course
and prognosis. Catastrophic antiphospholipid syndrome is an uncommon feature in SLE and
is often fatal. We report a case of fatal systemic lupus erythematosus in a 17-year-old girl with
a catastrophic antiphospholipid syndrome who presented a pulmonary embolism and septic
shock due to a urinary tract infection. We discuss the nosology, clinical features, immune
disorders, treatment and prognosis of the disease.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Systemic lupus erythematosus (SLE) is a multisystemic
disease involving mainly the joints. Respiratory involve-
ment is rare apart from pleural. The disease is rare in
persons younger than20 years old. Catastrophic anti-
phospholipid syndrome (CAPS) is an uncommon feature in
SLE associated with antiphospholipid syndrome (APS).1e3 It
also has a high mortality.2 We report a case of fatal SLE in
a 17-year-old girl with CAPS who presented withseptic
shock and acute respiratory distress syndrome (ARDS).860 2362; fax: þ216 71 821
(I. Zendah).
ll rights reserved.Case report
A 17-year-old girl, without significant medical history, was
transferred to our department for suspicion of anaphylaxis
as she developed facial edema and maculopapular lesions
with nasolabial herpes that appeared 5 days after being
treated by amoxicillin and clavulanic acid. This drug was
administered since she complained from fever, cough, left
chest pain and fatigue. On admission there were skin
lesions, ulcerations of the labial mucosa, edema of the face
and the inferior limbs, pyrexia (temperature 38 C), low
blood pressure (blood pressureZ 100/60 mmHg) and
tachycardia (pulse rateZ 114 beats/min). Chest radiog-
raphy showed a basal pleuro-parenchymal consolidation.
Laboratory findings revealed anemia with hemoglobin level
148 I. Zendah et al.of 85 g/l, leukopenia (white blood cellsZ 3  109 cells/l)
and thrombopenia (plateletsZ 101  109 cells/l). Erythro-
cyte sedimentation rate was 70 mm. Blood gas analysis
showed PaO2Z 79 mmHg, PaCO2Z 28 mmHg. An electro-
cardiogram showed tachycardia (pulse rateZ 116 beats/
min) and right branch block. On echocardiography, pulmo-
nary arterial pressure was 40 mmHg and there was a small
pericardial effusion. A pulmonary embolism was then sus-
pected and heparin was given but the ultrasound imaging of
the venous system of the inferior limbs did not reveal
thrombosis. Protein electrophoresis showed: protide-
miaZ 42 g/l, albuminemiaZ 17 g/l and proteinur-
iaZ 3 g/l. A nephrotic syndrome was then diagnosed.
There was no renal insufficiency. Antinuclear, antinative
DNA, anti-Sm, anti-RNP and anticardiolipin antibodies were
positive. Thoracic CT scan angiography demonstrated
arterial pulmonary embolism of the left latero- and post-
erobasal arteries, a pericardial effusion and a consolidation
of the right superior lobe, and a right pleural effusion
(Fig. 1).
The diagnosis of SLE was made and prednisone 1 mg/kg
per day was administered on the seventh day of admission.
On the second day of treatment, the patient presented an
acute respiratory failure with SaO2Z 86%, a fever
(temperature 39.5 C) and diffuse abdominal pain. Chest
radiograph revealed a worsening of the abnormalities with
hilo-axillar alveolar and pleural condensations. An abdom-
inal ultrasonography revealed a peritoneal effusion. The
patient was transferred to the intensive care unit (ICU). A
purulent pleural effusion was diagnosed. Bronchoalveolar
lavage showed total cell countZ 420  103cells/l, neu-
trophilsZ 18%, lymphocytesZ 15%, eosinophilsZ 2% and
macrophagesZ 65%. Golde score was 40. The culture of
the bronchial liquid, the hemocultures and the urine
culture revealed Escherichia coli.
The diagnosis of catastrophic antiphospholipid syndrome
associated with sepsis was made. Cefotaxim and Cipro-
floxacin were administered. Nevertheless, the patient
presented hemodynamic instability requiring intubation
and ventilation. Heparin, corticosteroids and vasoactive
drugs were administered and hemodialysis was undergoneFigure 1 CT scan angiography. Arterial pulmonary embolism
of the left latero- and posterobasal arteries and pericardial
effusion.because of metabolic acidosis (pHZ 7.1, lactates
19 mmol/l). The volume of the pericardial effusion
increased without tamponade. There was no worsening of
the pulmonary arterial hypertension. Hemoglobin failed to
42 g/l and platelets to 14,000/mm3. The patient presented
an ARDS. The chest X-ray film showed a consolidation of the
right hemithorax (Fig. 2). Finally, the patient died 16 h
after her admission to the ICU as a result of septic shock
and multiorgan failure.
Discussion
The diagnosis of APS was made in our patient on the basis of
the presence of SLE criteria with positive anticardiolipin
antibody and pulmonary thrombosis. CAPS is a rapidly
progressive life-threatening disease that causes:
1 Multiple organ thrombosis (usually within a week)
resulting in multiple organ dysfunction syndrome
(MODS)
2 Pathological evidence of small vessel thrombosis
3 Evidence of systemic inflammatory response syndrome
(SIRS)
4 High risk of unusual organ involvement
5 Laboratory confirmation of the presence of anti-
phospholipid antibodies (aPL)4
Though microthrombosis is one of the typical markers of
a CAPS event, it may be difficult to confirm and the diag-
nosis in our patient could only be labeled as ‘‘probable’’
CAPS.2 The nephrotic syndrome could be due to the lupus or
to thrombosis of microvessels of the kidney, or to both of
these.Figure 2 Chest radiograph. Consolidation of the right
hemithorax.
Catastrophic antiphospholipid syndrome 149CAPS was first described in 1992. As it is rare, an inter-
national registry of patients (the CAPS registry) was created
in 2000, supported by the European Forum on Anti-
phospholipid Antibodies. As of July 2005, a total of 252
cases had been reported.5
Cervera et al.,2 in a series comprising 220 patients
included in website-based CAPS, found that CAPS occurs
most of the time in women aged from 7 to 74 years. The
majority of patients present with multiple organ involve-
ment at the time of CAPS. The main clinical manifestations
included renal (70%), pulmonary (66%), cutaneous (47%),
cerebral (60%) and cardiac (52%) involvement.2 Our patient
presented with pulmonary, cutaneous, cardiac and renal
involvement.
Acute respiratory distress syndrome (ARDS) is the most
common manifestation seen in 34% of CAPS patients2 with
a mortality rate of 52%.Thus some authors recommend that
the existence of ARDS in the context of an APS makes it
necessary to rule out the presence of the catastrophic
variant of this syndrome.6
Pulmonary embolism is encountered in 16% of patients
with CAPS.7 Cervera et al.8 reported on 100 patients with
APS associated with infections; there was pulmonary
involvement in 39 of them including ARDS in 24 cases,
pulmonary embolism in 18, pulmonary hemorrhage in 3 and
pulmonary hypertension in 1.
The occlusion of the vessels can affect not only pulmo-
nary arteries and small vessels but also large vessels, and
may affect several aortic branches.9
Anticardiolipin antibodies (aCL) are detected in 84% of
the patients, the lupus anticoagulant in 76%, the antinu-
clear antibodies in 62%, anti-double-stranded DNA in 36%4
and anti RNP in 8% of CAPS patients.7 Thrombocytopenia is
found in 63e68% of the patients and hemolytic anemia in
26e32%.2,7 All those abnormalities were found in our
patient.
As in our patient, in the 220 patients reported from the
CAPS registry, more than half had an infection as a precip-
itating factor to the CAPS and 4% had lupus flares.2 Patients
with lupus are prone to infections, and some authors have
found that infection is the first cause of death in lupus
patients.10 Presumed immunodeficiency mechanisms added
to the disease by itself11,12 appear to predispose to this
complication.13
CAPS may be preceded by urinary tract infection in 4% of
the cases, and general sepsis in 1% of cases.14 Urinary tract
infection, especially due to E. coli, is the first or second
cause of infection followed by respiratory tract infections
in SLE patients.11,13 Our patient presented with septic
shock with pulmonary involvement due to a urinary infec-
tion by E. coli.
APS and CAPS can be challenging to treat. Mortality
reaches almost half of the cases especially those presenting
with cardiac, renal, splenic, and adrenal involvement and
those havingSLE such as in our patient.2,6
The site and the extension of the vascular occlusions and
the degree of systemic inflammatory response are the
determinants of the treatment.
The combination of anticoagulation, steroids and drugs
reducing the aPL titers (plasmapheresis and/or intravenous
gammaglobulins) have the highest survival rate (70%).7 The
treatment of any precipitating factor is mandatory,especially antibiotic therapy if an infection is suspected.
Annane et al.15 showed that the use of steroids reduced the
risk of death in patients with septic shock.
Our patient received corticotherapy for SLE and heparin
for pulmonary embolism. Nevertheless, she developed
a multiorgan failure due to a CAPS within 48 h and even
continuing to be administered those treatments, she died in
16 h. Unfortunately, no plasmapheresis nor gammaglobulins
were administered.
Conclusion
SLE associated with CAPS is an extremely rare, distinct
cause of multiple organ failure resulting from widespread
thrombosis and SIRS; it may be revealed by many presen-
tations and may be fatal. The diagnosis and the treatment
are challenging for physicians. Awareness of this rare
syndrome would facilitate an early diagnosis to prescribe
life-saving multimodal therapies including anticoagulation,
corticosteroids and plasma exchange. A further under-
standing of the etiopathogenesis of CAPS might lead to
novel targeted therapies and further reduce the mortality
rate, which remains too high.Conflict of interest statement
None of the authors have a conflict of interest to declare in
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